Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 5.36

From 52W high−42.81%

Volume16.78M

Market capCNY 8.18B

P/E (TTM)−89.8x

P/S (TTM)4.7x

Div yield—

Key dataSep 18, 2026

Open

CNY 5.36

From 52W high

−42.81%

Volume

16.78M

Market cap

CNY 8.18B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

34.6x

P/E (TTM)

−89.8x

RSI (14)

49.3

MomentumView details →

1D Return

−3.63%

YTD Return

−14.10%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−89.8x

EV/EBITDA

34.6x

EV/Sales

4.8x

P/S (TTM)

4.7x

P/B (TTM)

1.6x

ProfitabilityView details →

Gross Margin

24.96%

Net Margin

−3.97%

EBITDA Margin

13.85%

ROE (TTM)

−1.49%

ROA (TTM)

−1.05%

Asset Turnover

0.26x

GrowthView details →

Revenue YoY

−1.88%

EPS YoY

+79.77%

FCF YoY

—

Revenue CAGR 3Y

−11.72%

EPS CAGR 3Y

+71.43%

EBITDA YoY

—

MomentumView details →

1D Return

−3.63%

YTD Return

−14.10%

1Y Return

−15.46%

RSI (14)

49.3

vs 50D SMA

+0.52%

vs 200D SMA

−13.09%

Capital & dividendView details →

Debt/Equity

0.22x

Current Ratio

1.20x

Quick Ratio

0.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

−50.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.86B

Net Income (TTM)

−73.86M

Op. CF (TTM)

−87.77M

Latest newsMore news →

Haixiang Pharmaceutical reported a net loss of 64.038 million yuan for the first half of 2026, turning from a profit in the same period last year.24d ago

Haixiang Pharmaceutical's wholly-owned subsidiary Zhejiang Haixiang Chuannan Pharmaceutical received approval from China's National Medical Products Administration for its adenosine cyclophosphate API, packaged in 4kg/drum, with registration approved but GMP compliance check still required before domestic production and sales.26d ago

Similar companies

华峰超纤300180.SZ 众泰汽车000980.SZ 阿石创300706.SZ 金杯电工002533.SZ 北方长龙301357.SZ 鸿合科技002955.SZ Find similar companies →

Latest newsMore news →

Haixiang Pharmaceutical reported a net loss of 64.038 million yuan for the first half of 2026, turning from a profit in the same period last year.24d ago Haixiang Pharmaceutical's wholly-owned subsidiary Zhejiang Haixiang Chuannan Pharmaceutical received approval from China's National Medical Products Administration for its adenosine cyclophosphate API, packaged in 4kg/drum, with registration approved but GMP compliance check still required before domestic production and sales.26d ago